Seres Therapeutics has secured a non‑dilutive grant of up to $3.6 million from the global antibacterial partnership CARB‑X to develop and manufacture an oral liquid formulation of its lead live biotherapeutic candidate, SER‑155.
The award will enable the company to produce a liquid version of SER‑155 that can be administered to patients who cannot swallow capsules, including intubated patients in intensive care units, thereby expanding the drug’s potential clinical reach.
SER‑155 has earned Breakthrough Therapy designation from the U.S. Food and Drug Administration and achieved a 77 % relative risk reduction in bloodstream infections in a Phase 1b study of patients undergoing allogeneic hematopoietic stem cell transplantation.
The funding will support the next steps toward a Phase 2 trial, including scale‑up of manufacturing and formulation development, and will strengthen Seres’ competitive position in the live biotherapeutics market.
Seres previously received CARB‑X support for SER‑155 in 2017 during its preclinical stage, and the company has recently sold its first FDA‑approved microbiome therapeutic, VOWST™, to Nestlé Health Science in September 2024.
Management noted that the non‑dilutive grant will help offset the company’s ongoing cash burn and accelerate progress toward regulatory milestones, while the FDA has provided constructive feedback on the design of a well‑powered Phase 2 study that Seres is finalizing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.